ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,945
-0,07%
Bitcoin
64 545,78
-0,42%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PMV Pharmaceuticals Inc (PMVP)

  7. PMV Pharmaceuticals Inc (PMVP) Actualités

PMVP

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PMVP
DateHeureSourceTitreSymboleSociété
10/06/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
07/06/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
30/05/202413h00GlobeNewswire Inc.PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202413h00Business WireFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414h00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
27/03/202413h00GlobeNewswire Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/03/202421h01GlobeNewswire Inc.PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
26/02/202414h00GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
24/01/202415h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayNASDAQ:PMVPPMV Pharmaceuticals Inc
11/01/202422h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202422h01GlobeNewswire Inc.PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202314h00GlobeNewswire Inc.PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202318h30GlobeNewswire Inc.PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202318h00GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarNASDAQ:PMVPPMV Pharmaceuticals Inc
20/09/202322h05GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:PMVPPMV Pharmaceuticals Inc
09/08/202314h00GlobeNewswire Inc.PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/06/202323h56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PMVPPMV Pharmaceuticals Inc
09/06/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
06/06/202322h01GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
10/05/202314h00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/05/202312h20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314h05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314h03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314h02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202314h06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202314h00GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202313h03Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:PMVPPMV Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PMVP

Dernières Valeurs Consultées

AQSE
DUKE.GB
Duke Capital
CRTO
FLRUSD
Flare Network
BIT
S29671
Societe Generale Effekten
ASX
BSLKOC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés